Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232653 | 1.00 | GABRR1 (0.46) | GABRR1GGT1SMN1; SMN2CPB2PLA2G2A | |
| SCHEMBL3188611 | 1.00 | GABRR1 (0.46) | GABRR1GGT1SMN1; SMN2CPB2PLA2G2A | |
| Trifluoroacetic Acid SCHEMBL3611486 | 0.89 | GABRR1 (0.38) | GABRR1GGT1SMN1; SMN2CPB2PLA2G2A | |
| SCHEMBL7209148 | 0.88 | SMN1; SMN2 (0.42) | GABRR1SMN1; SMN2CPB2PLA2G2APLA2G5 | |
| SCHEMBL27698867 | 0.88 | SMN1; SMN2 (0.42) | GABRR1SMN1; SMN2CPB2PLA2G2APLA2G5 | |
| SCHEMBL4622349 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2PLA2G2APLA2G5SLC7A5ALDH1A1 | |
| SCHEMBL526345 | 0.85 | GABRR1 (0.45) | GABRR1GGT1SMN1; SMN2CPB2CA1 | |
| SCHEMBL3470018 | 0.83 | ALDH1A1 (0.52) | GABRR1GGT1ALDH1A1CA1CA2 | |
| SCHEMBL2153099 | 0.83 | GABRR1 (0.43) | GABRR1GGT1SMN1; SMN2CPB2CA1 | |
| SCHEMBL4866552 | 0.83 | GABRR1 (0.43) | GABRR1GGT1SMN1; SMN2CPB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778225-A2 | PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS | Bristol-Myers Squibb Company (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006019886-A2 | PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | claimed |
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-02 | — | — | US | disclosed |
| EP-3897644-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-1747021-B1 | SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES | SQUIBB & SONS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-1747021-B1 | SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES | SQUIBB & SONS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-1940470-B1 | Antibody-drug conjugates and their use | MEDAREX INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-7691962-B2 | Chemical linkers and conjugates thereof | MEDAREX, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| CN-101312748-A | Antibody-drug conjugates and methods of use | MEDAREX INC (US) | 2008-11-26 | — | — | CN | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2007038658-A2 | ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MEDAREX, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| EP-1747021-A2 | SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES | Medarex, Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060024317-A1 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC (US) | 2006-02-02 | — | — | US | disclosed |
| WO-2005112919-A2 | SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES | MEDAREX, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | GABRR1 1845/4885GGT1 2581/4885SMN1; SMN2 4348/4885 |
| US-20060024317-A1 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | CD74, HSP90B1, LY96 | GABRR1 2892/4885GGT1 134/4885SMN1; SMN2 1727/4885 |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | GABRR1 1845/4885GGT1 2581/4885SMN1; SMN2 4348/4885 |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | CD47, ANTXR2, CD2BP2 | GABRR1 409/4885GGT1 226/4885SMN1; SMN2 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.